GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.
"The agreement with GlaxoSmithKline will be a major boost for the AB-Biotics turnover in the coming years,” saidMiquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics.
In Brazil, GSK will promote Neurofarmagen, a genetic test developed by AB-Biotics which identifies the safest and most appropriate medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. The product will be launched this year in Brazil, where according to estimates by AB-Biotics, there are one million potential patients eligible for Neurofarmagen.
The test is currently marketed in Spain by Almirall following the agreement signed last October.